CYTOKINETICS INC
For the period ended Sep 30, 2026. Filed Nov 4, 2026.
View on SEC.govAbout this filing
A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.
Sep 30, 2026 · Filed Nov 4, 2026
CYTK$56.18+1.9%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Condensed Consolidated Statements of Stockholders’ Deficit
(In thousands, except share data) (Unaudited)
| Common Stock · AdditionalPaid-In · AccumulatedOtherComprehensive · Accumulated · TotalStockholders’ | ||||||
|---|---|---|---|---|---|---|
| Shares | Amount | Capital | (Loss) Income | Deficit | Deficit | |
| Balance, December 31, 2025 | 122,943,172 | $123 | $2,826,341 | $630 | $(3,486,719) | $(659,625) |
| Exercise of stock options | 403,208 | — | 11,346 | — | — | 11,346 |
| Vesting of restricted stock units, net of taxes withheld | 891,443 | 1 | (841) | — | — | (840) |
| Stock-based compensation | — | — | 30,824 | — | — | 30,824 |
| Unrealized loss on available-for-sale securities, net | — | — | — | (1,838) | — | (1,838) |
| Foreign currency translation adjustments | — | — | — | (404) | — | (404) |
| Net loss | — | — | — | — | (206,031) | (206,031) |
| Balance, March 31, 2026 | 124,237,823 | 124 | 2,867,670 | (1,612) | (3,692,750) | (826,568) |
| Exercise of stock options | 968,077 | 1 | 33,657 | — | — | 33,658 |
| Vesting of restricted stock units, net of taxes withheld | 137,636 | — | (1,527) | — | — | (1,527) |
| Issuance of common stock under Employee Stock Purchase Plan | 77,383 | — | 4,344 | — | — | 4,344 |
| Issuance of common stock in public offering, net of issuance costs | 11,338,028 | 11 | 760,137 | — | — | 760,148 |
| Issuance of common stock upon conversion of convertible notes | 2,002,817 | 2 | 21,065 | — | — | 21,067 |
| Stock-based compensation | — | — | 36,367 | — | — | 36,367 |
| Unrealized loss on available-for-sale securities, net | — | — | — | (1,770) | — | (1,770) |
| Foreign currency translation adjustments | — | — | — | (444) | — | (444) |
| Net loss | — | — | — | — | (198,762) | (198,762) |
| Balance, June 30, 2026 | 138,761,764 | 138 | 3,721,713 | (3,826) | (3,891,512) | (173,487) |
| Exercise of stock options | 375,462 | 1 | 12,408 | — | — | 12,409 |
| Vesting of restricted stock units, net of taxes withheld | 83,220 | — | (918) | — | — | (918) |
| Stock-based compensation | — | — | 35,458 | — | — | 35,458 |
| Unrealized loss on available-for-sale securities, net | — | — | — | (4,228) | — | (4,228) |
| Foreign currency translation adjustments | — | — | — | (336) | — | (336) |
| Net loss | — | — | — | — | (190,069) | (190,069) |
| Balance, September 30, 2026 | 139,220,446 | $139 | $3,768,661 | $(8,390) | $(4,081,581) | $(321,171) |
| Common Stock · AdditionalPaid-In · AccumulatedOtherComprehensive · Accumulated · TotalStockholders’ | ||||||
|---|---|---|---|---|---|---|
| Shares | Amount | Capital | (Loss) Income | Deficit | Deficit | |
| Balance, December 31, 2024 | 118,209,139 | $118 | $2,563,876 | $2,398 | $(2,701,764) | $(135,372) |
| Exercise of stock options | 351,985 | — | 7,651 | — | — | 7,651 |
| Vesting of restricted stock units, net of taxes withheld | 659,179 | 1 | (13) | — | — | (12) |
| Stock-based compensation | — | — | 23,549 | — | — | 23,549 |
| Unrealized loss on available-for-sale securities, net | — | — | — | (541) | — | (541) |
| Foreign currency translation adjustments | — | — | — | (312) | — | (312) |
| Net loss | — | — | — | — | (161,376) | (161,376) |
| Balance, March 31, 2025 | 119,220,303 | 119 | 2,595,063 | 1,545 | (2,863,140) | (266,413) |
| Exercise of stock options | 219,077 | — | 3,868 | — | — | 3,868 |
| Vesting of restricted stock units, net of taxes withheld | 55,056 | — | (514) | — | — | (514) |
| Issuance of common stock under Employee Stock Purchase Plan | 109,116 | — | 2,877 | — | — | 2,877 |
| Stock-based compensation | — | — | 27,535 | — | — | 27,535 |
| Unrealized loss on available-for-sale securities, net | — | — | — | (851) | — | (851) |
| Foreign currency translation adjustments | — | — | — | (852) | — | (852) |
| Net loss | — | — | — | — | (134,370) | (134,370) |
| Balance, June 30, 2025 | 119,603,552 | 119 | 2,628,829 | (158) | (2,997,510) | (368,720) |
| Exercise of stock options | 321,536 | 1 | 6,934 | — | — | 6,935 |
| Vesting of restricted stock units | 38,684 | — | — | — | — | — |
| Shares withheld related to net share settlement of equity awards | (13,118) | — | (720) | — | — | (720) |
| Induced conversion of convertible notes | 2,168,806 | 2 | 116,670 | — | — | 116,672 |
| Stock-based compensation | — | — | 30,696 | — | — | 30,696 |
| Unrealized gain on available-for-sale securities, net | — | — | — | 167 | — | 167 |
| Foreign currency translation adjustments | — | — | — | 25 | — | 25 |
| Net loss | — | — | — | — | (306,178) | (306,178) |
| Balance, September 30, 2025 | 122,119,460 | $122 | $2,782,409 | $34 | $(3,303,688) | $(521,123) |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.